The generation of a pharmacophore model is a challenging process, which often requires the interaction of medicinal chemists. Given a number of ligands for a specific target, the aim is to identify the pharmacophore patterns that are responsible for the biological activities of chemical compounds. A recent study of optimal assignment methods has shown that the assignment of chemical substructures is able to detect active compounds in a data set \[[@B1]\]. Therefore, we investigated the possibility to use this technique to identify key features of a set of active compounds.

To determine important substructures of active compounds, we integrated n weight factors, where n is the number of substructures. The substructures were defined using the pharmacophore definitions of Phase 3.0 \[[@B2]\]. To define the individual weights of the pharmacophore patterns, we integrated a genetic algorithm which assigns weight factors to the previously defined patterns. The experimental setup was designed as follows: Given a data set with active compounds, the most active compound was selected as query structure for the experiment. The remaining active compounds were inserted into a background data set containing inactive compounds. The genetic algorithm evolved n weights for the pharmacophore patterns of the query structure. To evaluate the fitness of an individual, we performed a single query screening with the weights of the individual. During the optimization process, the BEDROC score \[[@B3]\] is optimized which puts emphasis on the early recognition performance. The result of the genetic algorithm was a weight vector that assigns each pharmacophore feature the weight of the best individual.

We evaluated our approach on a subset of the Directory of Useful Decoys that is suitable for ligand-based virtual screening \[[@B1]\]\[[@B4]\]. The query structure was extracted from the same complexed crystal structure used by Huang et al. \[[@B4]\] to determine the binding site of the protein.

The presented method is able to provide valuable information about key features that are important for the biological activity of a compound. Additionally, information of the protein structure is not needed. Therefore, the method can also be used to derive a pharmacophore model if no protein structure is available (e.g. GPCRs).
